FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
Portfolio Pulse from Michael Juliano
The FDA is expected to approve updated COVID-19 vaccines from Moderna, Pfizer, and possibly Novovax this week. This approval is in response to a significant summer outbreak in the U.S. Moderna and Pfizer have vaccines ready for distribution, while Novovax's vaccine will be available later this month. Stocks of these companies and related ETFs have shown gains in anticipation of the approval.
August 19, 2024 | 4:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
First Trust Nasdaq Pharmaceuticals ETF went up 1.19%, reflecting gains in Pfizer's stock.
The ETF's performance is positively impacted by Pfizer's stock increase, as it holds a significant position in pharmaceutical stocks.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 60
POSITIVE IMPACT
Invesco Nasdaq Biotechnology ETF edged up 1.28%, likely influenced by gains in Moderna and Pfizer stocks.
The ETF's increase is likely due to its holdings in Moderna and Pfizer, both of which saw stock gains in anticipation of FDA approvals.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 60
POSITIVE IMPACT
iShares Genomics Immunology and Healthcare ETF rose 0.89%, likely influenced by Novovax's stock surge.
The ETF's rise is likely due to its exposure to Novovax, which saw a significant stock increase, reflecting investor optimism.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 60
POSITIVE IMPACT
Langar Global HealthTech ETF, which includes Moderna, ticked up 0.37% as Moderna's stock gained.
The ETF's performance is positively influenced by Moderna's stock gain, reflecting the ETF's exposure to health tech stocks.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 60
POSITIVE IMPACT
Moderna is expected to receive FDA approval for its updated COVID-19 vaccine, which is ready for distribution. The stock gained 1.72% in anticipation.
The FDA approval of Moderna's updated vaccine is a significant regulatory milestone, likely boosting investor confidence and stock price. The stock's recent gain reflects positive market sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Novovax's updated COVID-19 vaccine may receive FDA approval later, with distribution expected this month. The stock surged 5.98%.
While Novovax's vaccine approval is less certain, the potential for FDA approval and upcoming distribution has significantly boosted its stock, reflecting investor optimism.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Pfizer, in collaboration with BioNTech, is set to receive FDA approval for its updated COVID-19 vaccine. The stock rose 1.55% in anticipation.
The anticipated FDA approval of Pfizer's vaccine is a key regulatory event, expected to positively impact its stock price. The recent stock increase indicates market optimism.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90